Lancet. 1988 Feb 13;1(8581):318-21.
In a multicentre clinical trial 1267 patients with hemispheric stroke of duration 12 h or less and haematocrit of 35% or more were prospectively randomised to either haemodilution (by venesection and replacement of the same volume of dextran 40 in saline solution) or control treatment groups. In the haemodiluted group mean haematocrit declined from 43% to 37% at 48 h and this fall was maintained for seven days. A plain computed tomographic scan was obtained in all but 37 patients. 87% of the strokes were infarcts and 13% were haemorrhages. After six months the numbers of dead or severely disabled patients were equally distributed in the two treatment groups, and this was true also within the ischaemic and haemorrhagic subgroups. Furthermore, haemodilution did not improve outcome either in the group with very recent ischaemic stroke (less than 6 h) or in the subgroup with highest haematocrit (greater than 45%). Thus, moderate haemodilution does not improve the outcome in acute stroke patients.
在一项多中心临床试验中,1267例半球性卒中持续时间在12小时或以内且血细胞比容在35%或以上的患者被前瞻性随机分为血液稀释组(通过静脉放血并在盐溶液中补充相同体积的右旋糖酐40)或对照组。在血液稀释组中,平均血细胞比容在48小时时从43%降至37%,且这一降幅持续了7天。除37例患者外,所有患者均进行了普通计算机断层扫描。87%的卒中为梗死,13%为出血。6个月后,死亡或严重残疾患者的数量在两个治疗组中分布均匀,在缺血性和出血性亚组中也是如此。此外,血液稀释在近期缺血性卒中(小于6小时)组或血细胞比容最高(大于45%)的亚组中均未改善预后。因此,中度血液稀释并不能改善急性卒中患者的预后。